GlassScriptPhysician profile
David Bekhor
NPI 1194797837
$357,774.56
in general payments reported to CMS, 2019-2025
34 companies · $65K in 2025
The $65K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $7,193 · 2021: $17K · 2022: $44K · 2023: $105K · 2024: $100K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $223K · Food and Beverage: $18K · Travel and Lodging: $16K · Consulting Fee: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $223,426.00 |
| Food and Beverage | $17,775.56 |
| Travel and Lodging | $16,174.40 |
| Consulting Fee | $12,060.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $202,412.69 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $147,361.71 | 2019-2025 | Descovy, Biktarvy, Yeztugo |
| Janssen Biotech, INC. | $1,786.35 | 2019-2023 | Symtuza |
| Abbvie INC. | $1,312.37 | 2021-2025 | Avycaz, Vraylar, Linzess |
| Janssen Products, LP | $1,180.38 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $993.24 | 2019-2025 | Dificid, Pifeltro, Delstrigo |
| Bavarian Nordic A/S | $397.37 | 2025 | |
| Glaxosmithkline, LLC. | $294.62 | 2019-2023 | Shingrix |
| Shionogi INC | $274.44 | 2022-2025 | Fetroja |
| Melinta Therapeutics, LLC | $229.80 | 2019-2024 | Rezzayo, Orbactiv, Kimyrsa |
| Axsome Therapeutics, INC. | $146.80 | 2024-2025 | Auvelity |
| Allergan, INC. | $141.68 | 2019-2020 | |
| Amgen INC. | $125.00 | 2021 | |
| Eisai INC. | $123.77 | 2021 | |
| Hologic Sales and Service, LLC | $107.84 | 2024 | Aptima |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $105.24 | 2021-2023 | Egrifta, Trogarzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.88 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $73.87 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Idorsia Pharmaceuticals US INC | $66.71 | 2022-2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $60.49 | 2024-2025 | Nuzyra |
| Aimmune Therapeutics, INC. | $52.76 | 2025 | Vowst |
| Novo Nordisk INC | $50.04 | 2025 | |
| Napo Pharmaceuticals INC | $46.56 | 2024-2025 | Mytesi |
| Shield Therapeutics INC | $43.55 | 2025 | |
| Vanda Pharmaceuticals INC. | $30.68 | 2024 | Fanapt |
| Cleerly, INC. | $30.41 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Philips North America LLC | $27.99 | 2024 | (Ck7) Extended Holter |
| Daiichi Sankyo INC. | $27.17 | 2024 | Injectafer |
| Pfizer INC. | $25.42 | 2025 | |
| Lundbeck LLC | $22.36 | 2023 | Rexulti |
| Emd Serono, INC. | $21.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.09 | 2019 | |
| Seqirus USA INC | $17.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bekhor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.